167 related articles for article (PubMed ID: 35414436)
21. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
Tuccori M; Convertino I; Ferraro S; Cappello E; Valdiserra G; de Luca G; Franchini M; Focosi D
Expert Opin Drug Discov; 2022 Jun; 17(6):531-546. PubMed ID: 35361043
[TBL] [Abstract][Full Text] [Related]
22. Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.
Kurshan A; Snell LB; Prior L; Tam JCH; Graham C; Thangarajah R; Edgeworth JD; Nebbia G; Doores KJ
Oxf Open Immunol; 2023; 4(1):iqac012. PubMed ID: 36844257
[TBL] [Abstract][Full Text] [Related]
23. Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
Woopen C; Konofalska U; Akgün K; Ziemssen T
Front Immunol; 2022; 13():897748. PubMed ID: 35958567
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
Mayer C; VanHise K; Caskey R; Naqvi M; Burwick RM
Obstet Gynecol; 2021 Dec; 138(6):937-939. PubMed ID: 34583385
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system.
Mutoh Y; Umemura T; Ota A; Okuda K; Moriya R; Tago M; Soejima K; Noguchi Y; Bando T; Ota S; Sato T; Hirota S; Hagimoto S; Takei R; Sasano H; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Ichihara T; Kondoh Y
J Infect Chemother; 2022 Feb; 28(2):352-355. PubMed ID: 34863647
[TBL] [Abstract][Full Text] [Related]
27. Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia.
Hegazy AN; Krönke J; Angermair S; Schwartz S; Weidinger C; Keller U; Treskatsch S; Siegmund B; Schneider T
BMC Infect Dis; 2022 Jun; 22(1):537. PubMed ID: 35692034
[TBL] [Abstract][Full Text] [Related]
28. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
[TBL] [Abstract][Full Text] [Related]
29. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019.
Riccardo BA; Gabriele S; Nunzia E; Isabella DF; Biagio P; Maria F; Emanuela Z; Agnese G; Nicola SM; Giulio V; Riccardo S; Giuseppe B; Ivan G
Am J Perinatol; 2024 May; 41(S 01):e612-e616. PubMed ID: 35973799
[TBL] [Abstract][Full Text] [Related]
30. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
Koehler J; Ritzer B; Weidlich S; Gebhardt F; Kirchhoff C; Gempt J; Querbach C; Hoffmann D; Haller B; Schmid RM; Schneider J; Spinner CD; Iakoubov R
Infection; 2021 Dec; 49(6):1313-1318. PubMed ID: 34244967
[TBL] [Abstract][Full Text] [Related]
31. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity.
Nguyen H; Salkeld J; Agarwal S; Goodman A
Clin Infect Pract; 2021 Nov; 12():100089. PubMed ID: 34426799
[TBL] [Abstract][Full Text] [Related]
32. Regen-COV-2 Antibody Cocktail Mediated Clearance of SARS-COV-2 in an Immunocompromised Patient.
Basheer M; Saad E; Milhem F; Budman D; Assy N
Isr Med Assoc J; 2022 Nov; 24(11):695-696. PubMed ID: 36436032
[TBL] [Abstract][Full Text] [Related]
33. Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis.
Kakinoki Y; Yamada K; Tanino Y; Suzuki K; Ichikawa T; Suzuki N; Asari G; Nakamura A; Kukita S; Uehara A; Saito S; Kuroda S; Sakagami H; Nagashima Y; Takahashi K; Suzuki S
Int J Infect Dis; 2022 Apr; 117():189-194. PubMed ID: 35176486
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 Therapeutics and Vaccines: A Race to Save Lives.
Bebenek I; Bannister R; Dubinion J; Fortin M; Liu M; Motter AL; Rohde CM; Wrzesinski C
Toxicol Sci; 2022 Jan; 185(2):119-127. PubMed ID: 34735018
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing Monoclonal Antibodies for Coronavirus Disease 2019 (COVID-19) in Pregnancy: A Case Series.
Richley M; Rao RR; Afshar Y; Mei J; Mok T; Vijayan T; Weinstein S; Pham CU; Madamba J; Shin CS; Suda D; Han CS
Obstet Gynecol; 2022 Mar; 139(3):368-372. PubMed ID: 35115451
[TBL] [Abstract][Full Text] [Related]
36. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
[No Abstract] [Full Text] [Related]
37. Casirivimab/Imdevimab: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
[TBL] [Abstract][Full Text] [Related]
38. Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.
Li D; Xu M; Hooper AT; Rofail D; Mohammadi KA; Chen Y; Ali S; Norton T; Weinreich DM; Musser BJ; Hamilton JD; Geba GP
Sci Rep; 2023 Aug; 13(1):12784. PubMed ID: 37550377
[TBL] [Abstract][Full Text] [Related]
39. Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database.
Takemoto K
Oncology; 2024; 102(3):195-205. PubMed ID: 37666220
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab.
Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C
Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
